Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Lise M, Verhoef"'
Autor:
Jeffrey van der Ven, Bart J F van den Bemt, Liset van Dijk, Merel Opdam, Lex L Haegens, Johanna E Vriezekolk, Lise M Verhoef
Publikováno v:
JMIR Human Factors, Vol 10, p e44885 (2023)
BackgroundImplementation of eHealth is progressing slowly. In-depth insight into patients’ preferences and needs regarding eHealth might improve its use. ObjectiveThis study aimed to describe when patients want to use eHealth, how patients want to
Externí odkaz:
https://doaj.org/article/03a06965bb0a48868731e2416135db3d
Autor:
Frouwke Veenstra, Lise M. Verhoef, Merel Opdam, Alfons A. den Broeder, Wing-Yee Kwok, Inger L. Meek, Cornelia H. M. van den Ende, Marcel Flendrie, Noortje van Herwaarden
Publikováno v:
BMC Rheumatology, Vol 6, Iss 1, Pp 1-6 (2022)
Abstract Objective Gout and diabetes mellitus type 2 (DM) frequently co-exist. The pharmacological effects of metformin may include anti-inflammatory and urate lowering effects. The objective of this study was to test these effects in patients with g
Externí odkaz:
https://doaj.org/article/cbf6b93851664781b72edd639b1649ec
Autor:
Céleste J.T. van der Togt, Lise M. Verhoef, Bart J.F. van den Bemt, Nathan den Broeder, Rob ter Heine, Alfons A. den Broeder
Publikováno v:
Therapeutic Advances in Musculoskeletal Disease, Vol 14 (2022)
Background: Tofacitinib is a Janus Kinase (JAK) inhibitor used for the treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA), dosed as 5 mg twice daily (BID). It is primarily metabolized by the cytochrome P-3A (CYP3A) enzyme, and there
Externí odkaz:
https://doaj.org/article/a1142d7178994bf980659960cd087b8a
Autor:
Alfons A den Broeder, Paco M J Welsing, Bart J F van den Bemt, Lise M Verhoef, Maike H M Wientjes
Publikováno v:
RMD Open, Vol 8, Iss 2 (2022)
Objectives In this systematic review, we aim to identify laboratory biomarkers that predict response to tumour necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA).Methods EMBASE, PubMed and Cochrane Library (CENTRAL) were sea
Externí odkaz:
https://doaj.org/article/76659779552b436f994c57bf80320a8c
Publikováno v:
BMC Rheumatology, Vol 4, Iss 1, Pp 1-10 (2020)
Abstract Background Dose loading of biological disease modifying anti-rheumatic drugs (bDMARDs) in auto-immune rheumatic diseases (AIRDs) is performed to achieve steady state drug concentrations earlier after treatment start compared to dosing regime
Externí odkaz:
https://doaj.org/article/4ed788a64380499ab9aca78da9b993e8
Autor:
Celia A. J. Michielsens, Nadine Boers, Nathan den Broeder, Mark H. Wenink, Aatke van der Maas, Elien A. M. Mahler, Michelle L. M. Mulder, Désirée van der Heijde, Frank H. J. van den Hoogen, Lise M. Verhoef, Alfons A. den Broeder
Publikováno v:
Trials, Vol 21, Iss 1, Pp 1-12 (2020)
Abstract Background Tumour necrosis factor inhibitors (TNFi) are effective in the treatment of patients with spondyloarthritis (SpA), including psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). However, these drugs come with some disadva
Externí odkaz:
https://doaj.org/article/57219f3f31494167bd5e7678b9c9b2fc
Autor:
Alfons A. den Broeder, Lise M. Verhoef, Jaap Fransen, Rogier Thurlings, Bart J. F. van den Bemt, Steven Teerenstra, Nadine Boers, Nathan den Broeder, Frank H. J. van den Hoogen
Publikováno v:
Trials, Vol 18, Iss 1, Pp 1-9 (2017)
Abstract Background A standard low-dosing schedule of rituximab (RTX; 2 × 500 mg or 1 × 1000 mg) is as effective for active rheumatoid arthritis (RA) as the registered dose (2 × 1000 mg). Moreover, several small uncontrolled studies suggest that e
Externí odkaz:
https://doaj.org/article/40d9d58a72df4917856fefc637c4679e
Autor:
Merel A A, Opdam, Sophie, Benoy, Lise M, Verhoef, Sandra, Van Bijnen, Femke, Lamers-Karnebeek, René A M, Traksel, Petra, Vos, Alfons A, den Broeder, Jasper, Broen
Publikováno v:
Clinical Pharmacology and Therapeutics, 111, 1061-1065
Clinical Pharmacology and Therapeutics, 111, 5, pp. 1061-1065
Clinical Pharmacology and Therapeutics, 111, 5, pp. 1061-1065
Contains fulltext : 251806.pdf (Publisher’s version ) (Closed access) Patients with inflammatory rheumatic diseases (IRDs) do not have an increased risk for coronavirus disease 2019 (COVID-19) compared with the general population. However, it remai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97dd7dd107015e209f394a33d03e8446
https://doi.org/10.1002/cpt.2551
https://doi.org/10.1002/cpt.2551
Autor:
Maike H M Wientjes, Titia M G Gijzen, Nathan den Broeder, Karien Bloem, Annick de Vries, Bart J F van den Bemt, Alfons A den Broeder, Lise M Verhoef
Publikováno v:
Rheumatology, 61, 10, pp. 3974-3980
Rheumatology, 61, 3974-3980
Rheumatology, 61, 3974-3980
Objectives The REDO trial (REtreatment with Rituximab in RhEumatoid arthritis: Disease Outcome after Dose Optimisation) showed that ultra-low-dose rituximab (500 mg or 200 mg) was similarly effective to a 1000 mg dosage in the majority of RA patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41cd1c027d1b60a6785339e1ab4337aa
https://hdl.handle.net/2066/283275
https://hdl.handle.net/2066/283275
Publikováno v:
Rheumatology Advances in Practice, 7, 1
Rheumatology Advances in Practice, 7
Rheumatology Advances in Practice, 7
Objectives Immunomodulatory agents are safe and effective as treatment for various immune-mediated inflammatory diseases (IMIDs), but are associated with a slightly increased infection risk. It is uncertain whether, in the event of an infection, cont
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa444f60f0c96beb92e52ae7865116e9
https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/291040
https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/291040
